SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is trending due to a significant surge following FDA Breakthrough Therapy Designation for its drug targeting a rare disease, Sanfilippo syndrome type B. The community is discussing the potential for continued gains, a possible short squeeze, and comparing it to other high-flying stocks. Some traders express caution, pointing to the company's financials and the potential for a pullback, while others are excited about the long-term potential.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending after news of a multi-year AI compute deal with OpenAI, including potential stock warrants, fueled bullish sentiment. Community members are discussing the potential impact on market share and revenue, with some analysts raising price targets significantly. The conversation highlights a possible shift in the AI chip landscape and increased competition for Nvidia.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending due to community enthusiasm and repeated mentions across social platforms. Community members are drawing comparisons to Bitcoin, emphasizing Weedcoin's potential, and promoting its unique culture. Some users are alleging coordinated efforts to artificially inflate the token's popularity.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation ($ACHR) is trending amid speculation of a partnership with Tesla ($TSLA) after a teaser video featuring both companies sparked rumors of collaboration within the eVTOL space. The community is actively discussing potential price targets, short squeeze opportunities, and whether this partnership is credible or simply hype. Despite liquidity and strong partnerships, concerns around cash burn and certification risks remain a key talking point.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

CRML is trending due to speculation around potential U.S. government investment in its Greenland rare earth project, fueled by a Reuters report, though a White House denial has created volatility. Community members are debating the validity of the reports and the broader implications for the company's future, with some viewing it as a strategic play for U.S. resource independence. The stock's price movement and high trading volume reflect the uncertainty and heightened interest surrounding these developments.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending amid ongoing discussions about its potential in energy-efficient AI and comparisons to other quantum computing stocks. Community members are pointing to increased institutional investment from Vanguard, while others debate the company's valuation and long-term commercial viability. There's also chatter about potential partnerships and buyout scenarios, contributing to the stock's recent upward momentum.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending as it begins trading on the NASDAQ, with community members discussing its potential in the quantum computing space and comparing its valuation to sector peers. Optimism is fueled by a partnership with a Korean payment processor and the company's focus on quantum-secure stablecoin settlements. Despite some volatility and concerns about potential dilution, many see long-term growth potential and undervalued status.

Siyata Mobile, Inc. engages in the provision of cellular communications systems for enterprise customers. It specializes in connected vehicle products for professional fleets, marketed under the Uniden Cellular and Siyata brands. The firm operates through the following geographical segments: Europe, the Middle East and Africa; Unites States; Canada; and Australia and New Zealand. The company was founded by Marc Seelenfreund on October 15, 1986 and is headquartered in Montreal, Canada.

Siyata Mobile Inc

Siyata Mobile ($SYTA) is trending due to the completion of its merger with Core Gaming, rebranding as Core AI Holdings ($CHAI). The company will undergo a 1-for-4 reverse stock split, leading to community discussion around its potential impact and future valuation. There is speculation regarding a possible squeeze and the influence of major shareholders, with some anticipating significant upward movement.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PYPL is trending amid discussions about a potential breakout and recent news of a partnership in India, sparking optimism among some traders. However, others express concerns about the company's growth prospects and discuss its historical performance, with some highlighting its struggle to sustain gains. Community members are actively debating potential price movements and the stock's long-term value, with differing opinions on its future direction.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending as investors discuss the implications of a recent private placement and its impact on the company's cash position and future strategy. Community members are debating the stock's valuation, potential acquisitions, and its position relative to other quantum computing companies. Some are bullish, citing the strong institutional demand, while others express concerns about dilution and question the long-term commercial viability of the technology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 0.00% and -48.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a...

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the companys...

Shares of Viridian Therapeutics surged nearly 18% at the open on Monday to a nearly three-week high after the company reported promising trial data for its experimental drug veligrotug, aimed at treating chronic thyroid eye disease (TED).Viridian announced that in a late-stage trial, 56% of veligrotug-treated patients experienced a reduction in proptosis, or abnormal eye bulging, achieving a mean reduction of 2.34 mm.&nbsp;Additionally, 56% of participants reported reduced diplopia, or double vision, with 32% achieving complete resolution.&nbsp;The trial also delivered a 2.9-point mean reduction in inflammatory signs and symptoms from baseline, with the drug being well-tolerated and associated with only mild adverse events.Thyroid eye disease, which causes inflammation and damage to the tissues surrounding the eye, affects an estimated 90 to 300 people per 100,000 in the U.S.Viridian confirmed that it remains on track to submit a marketing application for veligrotug to U.S. regulators in the second half of 2025.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/VRDN_sentiment_and_message_volume_Dec_16_bd76e824a8.png" alt="VRDN sentiment and message volume Dec 16.png" width="1318" height="324"><figcaption>VRDN sentiment and message volume Dec 16 as of 9:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Viridian’s stock turned ‘extremely bullish’, with the ticker entering the platform’s top 15 trending symbols.&nbsp;One user described the news as making the stock a “long-term hold for me.”&nbsp;Another hinted that veligrotug could offer better returns for Viridian than Tepezza, an FDA-approved TED drug marketed by Horizon Therapeutics, which was acquired by Amgen in October 2023 for $27.8 billion.Viridian also expressed optimism about its VRDN-003 program, an IGF-1R antibody in development for TED.&nbsp;The company said the combined results from the THRIVE and THRIVE-2 trials bolster confidence that VRDN-003 will deliver positive topline data by the first half of 2026, enabling a BLA submission in the second half of the same year.&nbsp;Still, Viridian stock remains down about 20% year-to-date, as of its last close.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Viridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial Data

The company confirmed that it remains on track to submit a marketing application for veligrotug to U.S. regulators in the second half of 2025.

Equity

The company confirmed that it remains on track to submit a marketing application for veligrotug to U.S. regulators in the second half of 2025.


Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive...

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to...

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent...

Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the company or Viridian), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare...

Analyst Expectations For Viridian Therapeutics's Future

Latest Ratings for VRDN
 DateFirmActionFromTo Mar 2022JMP SecuritiesMaintainsMarket Outperform Nov 2021SVB LeerinkInitiates Coverage OnOutperform Nov 2021JMP SecuritiesMaintainsMarket Outperform...

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

VRDN
Viridian Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VRDN News

VRDN Viridian Therapeutics Inc